[Neuro-endocrine disorders in cardiac insufficiency: therapeutic consequences].

A. Castaigne,A. Duval-Moulin,J. Dubois-Randé,P. Merlet,L. Hittinger

1988-06-23

Abstract:

What problem does this paper attempt to address?

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Min Han,Shiying Zhou,Zunde Liao,Chen Zishan,Xiangting Yi,Chuanbin Wu,Dongmei Zhang,Yao He,Kam W Leong,Yiling Zhong

DOI: https://doi.org/10.1016/j.biomaterials.2024.122934

IF: 14

2024-01-01

Biomaterials

Abstract:Immunotherapy has transformed cancer treatment, but its efficacy is often limited by the immunosuppressive characteristics of the tumor microenvironment (TME), which are predominantly influenced by the metabolism of cancer cells. Among these metabolic pathways, the indoleamine 2,3-dioxygenase (IDO) pathway is particularly crucial, as it significantly contributes to TME suppression and influences immune cell activity. Additionally, inducing immunogenic cell death (ICD) in tumor cells can reverse the immunosuppressive TME, thereby enhancing the efficacy of immunotherapy. Herein, we develop CGDMRR, a novel bimetallic peroxide-based nanodrug based on copper-cerium peroxide nanoparticles. These nanotherapeutics are engineered to mitigate tumor hypoxia and deliver therapeutics such as 1-methyltryptophan (1MT), glucose oxidase (GOx), and doxorubicin (Dox) in a targeted manner. The design aims to alleviate tumor hypoxia, reduce the immunosuppressive effects of the IDO pathway, and promote ICD. CGDMRR effectively inhibits the growth of 4T1 tumors and elicits antitumor immune responses by leveraging immunometabolic interventions and therapies that induce ICD. Furthermore, when CGDMRR is combined with a clinically certified anti-PD-L1 antibody, its efficacy in inhibiting tumor growth is enhanced. This improved efficacy extends beyond unilateral tumor models, also affecting bilateral tumors and lung metastases, due to the activation of systemic antitumor immunity. This study underscores CGDMRR's potential to augment the efficacy of PD-L1 blockade in breast cancer immunotherapy.
An Oxidative Stress Nano-Amplifier for Improved Tumor Elimination and Combined Immunotherapy

Wei Zhang,Yijun Ran,Mi Yang,Yaqin Hu,Zhigang Wang,Yang Cao,Haitao Ran

DOI: https://doi.org/10.1002/adhm.202402349

2024-09-02

Abstract:Amplifying oxidative stress to disrupt intracellular redox homeostasis can accelerate tumor cell death. In this work, an oxidative stress amplifier (PP@T) is prepared for enhanced tumor oxidation therapy to reduce tumor growth and metastases. The nano-amplifier has been successfully constructed by embedding MTH1 inhibitor (TH588) in the PDA-coated porphyrin metal-organic framework PCN-224. The controllable-released TH588 is demonstrated from pores can hinder MTH1-mediated damage-repairing process by preventing the hydrolysis of 8-oxo-dG, thereby amplifying oxidative stress and exacerbating the oxidative DNA damage induced by the sonodynamic therapy of PP@T under ultrasound irradiation. Furthermore, PP@T can effectively induce immunogenic cell death to trigger systemic anti-tumor immune response. When administered in combination with immune checkpoint blockade, PP@T not only impedes the progression of the primary tumor but also achieves obvious antimetastasis in breast cancer murine models, including orthotopic and artificial whole-body metastasis models. Furthermore, the nanoplatform also provides photoacoustic imaging for in vivo treatment guidance. In conclusion, by amplifying oxidative stress and reactive oxygen species sensitized immunotherapy, this image-guided nanosystem shows potential for highly specific, effective combined therapy against tumor cells with negligible side-effects to normal cells which will provide a new insight for precise tumor treatment.
A Novel Nanomedicine Integrating Ferroptosis and Photothermal Therapy, Well-Suitable for PD-L1-mediated Immune Checkpoint Blockade

Yujun Bao,Guanghao Li,Siqi Li,Haishui Zhou,Ziqing Yang,Zhiqiang Wang,Rui Yan,Changhong Guo,Yingxue Jin

DOI: https://doi.org/10.1016/j.mtbio.2024.101346

IF: 8.2

2024-01-01

Materials Today Bio

Abstract:Immunotherapy based on immune checkpoint blockade has emerged as a promising treatment strategy; however, the therapeutic efficacy is limited by the immunosuppressive microenvironment. Here, we developed a novel immune-activated nanoparticle (Fc-SS-Fe/Cu) to address the issue of insufficient immune infiltration. Specifically, the structure of Fc-SS-Fe/Cu collapsed in response to the tumor microenvironment, the ferrocene and disulfide bonds and the released Fe/Cu ions can effectively generate ·OH and deplete GSH to increase oxidative stress, thereby inducing ferroptosis. Withal, the positive feedback mechanisms of "laser-triggered mild-temperature photothermal therapy (PTT), PTT accelerated ferroptosis and LPO accumulation, LPO mediated HSPs down-regulated to promote PTT," effectively triggers immunogenic cell death (ICD) in tumor cells, significantly enhancing their immunogenicity. Moreover, the O2-generating ability induced by Fc-SS-Fe/Cu could reverse the hypoxic tumor microenvironment, and importantly, the expression of PD-L1 on tumor cell surfaces could be effectively downregulated by inhibiting the HIF-1α pathways, thereby augmenting the effect of anti-PD-L1 (αPD-L1) therapy. Therefore, this study provides valuable strategies into enhancing PD-L1-mediated ICB therapy.
PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Li Du,Yao Gong,Xiaoying Zhang,Jide Sun,Fengxia Gao,Meiying Shen,Huili Bai,Tiantian Yang,Xiaoxue Cheng,Siqiao Li,Jian Peng,Zhangling Liu,Shijia Ding,Junman Chen,Wei Cheng

DOI: https://doi.org/10.1186/s12951-024-02700-4

2024-07-27

Abstract:Background: PD-1/PD-L1 blockade has become a powerful method to treat malignant tumors. However, a large proportion of patients still do not benefit from this treatment, due to low tumor immunogenicity and low tumor penetration of the agents. Recently, neutrophil elastase has been shown to induce robust tumor immunogenicity, while the insufficient enzyme activity at the tumor site restricted its anti-tumor application. Here, we designed polyethyleneimine-modified neutrophil elastase (PEI-elastase) loaded with PD-L1small interfering RNA (PD-L1 siRNA) for improving enzymatic activity and delivering siRNA to tumor, which was expected to solve the above-mentioned problems. Results: We first demonstrated that PEI-elastase possessed high enzymatic activity, which was also identified as an excellent gene-delivery material. Then, we synthesized anti-tumor lipopolymer (P-E/S Lip) by encapsulating PEI-elastase and PD-L1siRNA with pH-responsive anionic liposomes. The P-E/S Lip could be rapidly cleaved in tumor acidic environment, leading to exposure of the PEI-elastase/PD-L1 siRNA. Consequently, PEI-elastase induced powerful tumor immunogenicity upon direct tumor killing with minimal toxicity to normal cells. In parallel, PEI-elastase delivered PD-L1siRNA into the tumor and reduced PD-L1 expression. Orthotopic tumor administration of P-E/S Lip not only attenuated primary tumor growth, but also produced systemic anti-tumor immune response to inhibit growth of distant tumors and metastasis. Moreover, intravenous administration of P-E/S Lip into mice bearing subcutaneous tumors leaded to an effective inhibition of established B16-F10 tumor and 4T1 tumor, with histological analyses indicating an absence of detectable toxicity. Conclusions: In our study, a protease-based nanoplatform was used to cooperatively provoke robust tumor immunogenicity and down-regulate PD-L1 expression, which exhibited great potential as a combination therapy for precisely treating solid tumors.
Radiation-activated PD-L1 aptamer-functionalized nanoradiosensitizer to potentiate antitumor immunity in combined radioimmunotherapy and photothermal therapy

Bo Chen,Yinbo He,Long Bai,Shulin Pan,Yinggang Wang,Min Mu,Rangrang Fan,Bo Han,Peter Ernst Huber,Bingwen Zou,Gang Guo

DOI: https://doi.org/10.1039/d4tb01831a

IF: 7.571

2024-10-09

Journal of Materials Chemistry B

Abstract:Reactive oxygen species (ROS)-mediated immunogenic cell death (ICD) is crucial in radioimmunotherapy by boosting innate antitumor immunity. However, the hypoxic tumor microenvironment (TME) often impedes ROS production, limiting the efficacy of radiotherapy. To tackle this challenge, a combination therapy involving radiotherapy and immune checkpoint blockade (ICB) with anti-PD-L1 has been explored to enhance antitumor effects and reprogram the immunosuppressive TME. Here, we introduce a novel PD-L1 aptamer-functionalized nanoradiosensitizer designed to augment radiotherapy by increasing X-ray deposition specifically at the tumor site. This innovative X-ray activated nanoradiosensitizer, comprising gold-MnO2 nanoflowers, efficiently enhances ROS generation under single low-dose radiation and repolarizes M2-like macrophages, thereby boosting antitumor immunity. Additionally, the ICB inhibit BMS-202 synergizes with the PD-L1 aptamer-assisted nanoradiosensitizer to block the PD-L1 receptor, promoting T cell activation. Furthermore, this nanoradiosensitizer exhibits exceptional photothermal conversion efficacy, amplifying the ICD effect. The PD-L1-targeted nanoradiosenesitizer effectively inhibits primary tumor growth and eliminates distant tumors, underscoring the potential of this strategy in optimizing both radioimmunotherapy and photothermal therapy.

materials science, biomaterials
Nanomedicine Integrating the Lipidic Derivative of 5-Fluorouracil, Miriplatin and PD-L1 Sirna for Enhancing Tumor Therapy

An Lu,Yuhao Guo,Yi Yan,Lin Zhai,Xiangyu Wang,Weiran Cao,Zijie Li,Zhixia Zhao,Yujie Shi,Yuanjun Zhu,Xiaoyan Liu,Huining He,Zhiyu Wang,Jian-Cheng Wang

DOI: https://doi.org/10.1016/j.cclet.2023.108928

IF: 9.1

2024-01-01

Chinese Chemical Letters

Abstract:Immunosuppressive microenvironments present critical problems in clinical chemotherapy. To regulate the tumor immune microenvironment for enhancing antitumor effect, a combination of immune checkpoint inhibitors (ICIs) with chemotherapeutics has been applied clinically. In this study, miriplatin (MiPt), the lipidic derivative of 5-fluorouracil (Fu-OA), as well as the programmed death ligand 1 (PD-L1) target siRNA (siPD-L1) were integrated into Lip-Pt/Fu@siPD-L1 nanoparticles (NPs) for chemo-immunotherapy. In vitro results showed that Lip-Pt/Fu@siPD-L1 NPs could exhibit effective siRNA gene silencing and promote the phagocytosis of tumor cells by macrophages. Furthermore, in vivo results revealed that Lip-Pt/Fu@siPD-L1 NPs showed significantly higher anti-tumor efficiency than that of the physical mixing of MiPt, 5-fluorouracil, and Lip@siPD-L1 NPs (delivery of siPD-L1 by liposomes). The best anti-tumor efficiency of Lip-Pt/Fu@siPD-L1 NPs resulted from the synergistic immunotherapeutic effects of MiPt and siPD-L1 based on the inhibition of CD47 expression and the downregulation of PD-L1 in tumor cells, which elicited a robust anti-tumor immune response through the activation of macrophage phagocytosis and immune checkpoint inhibition. The Lip-Pt/Fu@siPD-L1 NPs provide a potential strategy for tumor chemo-immunotherapy.
Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer

Guoyun Wan,Xuheng Chen,Haijiao Wang,Shenglei Hou,Qian Wang,Yuanyuan Cheng,Qian Chen,Yingge Lv,Hongli Chen,Qiqing Zhang

DOI: https://doi.org/10.1186/s12951-021-01094-x

IF: 10.2

2021-10-29

Journal of Nanobiotechnology

Abstract:Abstract Background Colorectal cancer is known to be resistant to immune checkpoint blockade (ICB) therapy. Sonodynamic therapy (SDT) has been reported to improve the efficacy of immunotherapy by inducing immunogenic cell death (ICD) of cancer. However, the SDT efficacy is extremely limited by Nrf2-based natural redox balance regulation pathway in cancer cells in response to the increased contents of reactive oxygen species (ROS). Nuclear-targeting strategy has shown unique advantages in tumor therapy by directly destroying the DNA. Thus it can be seen that Nrf2-siRNA augmented nuclear-targeting SDT could boost ICB therapy against colorectal cancer. Results The nuclear-targeting delivery system TIR@siRNA (TIR was the abbreviation of assembled TAT-IR780) with great gene carrier capacity and smaller diameter (< 60 nm) was designed to achieve the gene augmented nuclear-targeting SDT facilitating the anti-PD-L1 (programmed cell death-ligand-1) therapy against colorectal cancer. In CT26 cells, TIR@siRNA successfully delivered IR780 (the fluorescent dye used as sonosensitizer) into cell nucleus and Nrf2-siRNA into cytoplasm. Under US (utrasound) irradiation, TIR@siRNA notably increased the cytotoxicity and apoptosis-inducing activity of SDT through down-regulating the Nrf2, directly damaging the DNA, activating mitochondrial apoptotic pathway while remarkably inducing ICD of CT26 cells. In CT26 tumor-bearing mice, TIR@siRNA mediated gene enhanced nuclear-targeting SDT greatly inhibited tumor growth, noticeably increased the T cell infiltration and boosted D PPA-1 peptide-based anti-PD-L1 therapy to ablate the primary CT26 tumors and suppress the intestinal metastases. Conclusions All results demonstrate that TIR@siRNA under US irradiation can efficiently inhibit the tumor progression toward colorectal CT26 cancer in vitro and in vivo by its mediated gene augmented nuclear-targeting sonodynamic therapy. Through fully relieving the immunosuppressive microenvironment of colorectal cancer by this treatment, this nanoplatform provides a new synergistic strategy for enhancing the anti-PD-L1 therapy to ablate colorectal cancer and inhibit its metastasis. Graphical Abstract

biotechnology & applied microbiology,nanoscience & nanotechnology
Nrf2 silencing amplifies DNA photooxidative damage to activate the STING pathway for synergistic tumor immunotherapy

Shengjie Sun,Mian Yu,Liu Yu,Wenxin Huang,Meishu Zhu,Yanan Fu,Lingchen Yan,Qiang Wang,Xiaoyuan Ji,Jing Zhao,Meiying Wu

DOI: https://doi.org/10.1016/j.biomaterials.2023.122068

IF: 14

2023-05-01

Biomaterials

Abstract:Photodynamic therapy (PDT)-mediated antitumor immune response depends on oxidative stress intensity and subsequent immunogenic cell death (ICD) in tumor cells, yet the inherent antioxidant system restricts reactive oxygen species (ROS)-associated oxidative damage, which is highly correlated with the upregulated nuclear factor erythroid 2-related factor 2 (Nrf2) and the downstream products, such as glutathione (GSH). Herein, to overcome this dilemma, we designed a versatile nanoadjuvant (RI@Z-P) to enhance the sensitivity of tumor cells to oxidative stress via Nrf2-specific small interfering RNA (siNrf2). The constructed RI@Z-P could significantly amplify photooxidative stress and achieve robust DNA oxidative damage, activating the stimulator of interferon genes (STING)-dependent immune-sensing to produce interferon-β (IFN-β). Additionally, RI@Z-P together with laser irradiation reinforced tumor immunogenicity by exposing or releasing damage-associated molecular patterns (DAMPs), showing the prominent adjuvant effect for promoting dendritic cell (DC) maturation and T-lymphocyte activation and even alleviating the immunosuppressive microenvironment to some extent.

engineering, biomedical,materials science, biomaterials
A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy

Ming Li,Dong Zhao,Jianqin Yan,Xiaoheng Fu,Fashun Li,Gecen Liu,Yujiang Fan,Yan Liang,Xingdong Zhang

DOI: https://doi.org/10.1021/acsnano.4c00227

IF: 17.1

2024-05-21

ACS Nano

Abstract:Epirubicin (EPI) alone can trigger mildly protective autophagy in residual tumor cells, resulting in an immunosuppressive microenvironment. This accelerates the recurrence of residual tumors and leads to antiprogrammed death ligand 1 (anti-PD-1)/PD-L1 therapy resistance, posing a significant clinical challenge in tumor immunotherapy. The combination of checkpoint inhibitors targeting the PD-1/PD-L1 pathway and amplifying autophagy presents an innovative approach to tumor treatment, which can prevent tumor immune escape and enhance therapeutic recognition. Herein, we aimed to synthesize a redox-triggered autophagy-induced nanoplatform with SA&EA-induced PD-L1 inhibition. The hyaluronic acid (HA) skeleton and arginine segment promoted active nanoplatform targeting, cell uptake, and penetration. The PLGLAG peptide was cleaved by overexpressing matrix metalloproteinase-2 (MMP-2) in the tumor microenvironment, and the PD-L1 inhibitor D-PPA was released to inhibit tumor immune escape. The intense autophagy inducers, STF-62247 and EPI, were released owing to the cleavage of disulfide bonds influenced by the high glutathione (GSH) concentration in tumor cells. The combination of EPI and STF induced apoptosis and autophagic cell death, effectively eliminating a majority of tumor cells. This indicated that the SA&EA nanoplatform has better therapeutic efficacy than the single STF@AHMPP and EPI@AHMPTP groups. This research provided a way to set up a redox-triggered autophagy-induced nanoplatform with PD-L1 inhibition to enhance chemo-immunotherapy.
Peptide-Appended Nanosonosensitizers Targeting Tumor Glycolysis for Synergistic Sonodynamic-Immunometabolic Therapy of Spinal-Metastasized Tumors

Zhiyang Chen,Liang Chen,Yiqun Ma,Yuyi Liu,Qianyi Zhang,Hao Qin,Yu Chen,Bo Tian,Jian Dong

DOI: https://doi.org/10.1002/adma.202304246

IF: 29.4

2023-01-01

Advanced Materials

Abstract:Despite recent advancements in cancer immunotherapy, challenges have yet to be surmounted to achieve two major goals of magnifying antitumor immunity and remodeling the immunosuppressive tumor microenvironment. Here, a nanosystem (ODM-R) that integrates oxygen-deficient molybdenum oxide (ODM) nanosonosensitizers and R7 peptides with tumor metabolism regulation effects is designed and fabricated for synergistic sonodynamic-immunometabolic therapy of spinal-metastasized tumors. The ODM generates reactive oxygen species upon ultrasound irradiation to implement sonodynamic therapy (SDT), inducing cancer cell apoptosis and immunogenic cell death. The R7 attached on ODM markedly inhibits the uptake of glucose and excretion of lactic acid in cancer cells by perturbing the glycolysis process. The combination of SDT and tumor glycolysis obstruction by ODM-R guarantees satisfactory efficacy in synergizing with PD-L1 antibody to eradicate spinal-metastasized tumors, achieving concurrent sonodynamic-triggered immune activation and immunosuppressive tumor microenvironment remodeling. This work provides a proof-of-concept of nanosonosensitizers for boosting cancer immunotherapy by SDT and tumor metabolic regulation.
Rationally Integrated Precise ER‐targeted And Oxygen‐compensated Photodynamic Immunostimulant for Immunogenicity‐boosted Tumor Therapy

Yanrong Qian,Man Wang,Yulin Xie,Qianqian Sun,Minghong Gao,Chunxia Li

DOI: https://doi.org/10.1002/adhm.202301728

IF: 10

2023-08-23

Advanced Healthcare Materials

Abstract:Notwithstanding that immunotherapy has made eminent clinical breakthroughs, activating the immunogenicity and breaking the immunosuppressive tumor microenvironment (ITME) remains tempting yet challenging. Herein, a customized‐designed immunostimulant was engineered for attenuating ITME and eliciting an immune response to address this challenge head‐on. This immunostimulant was equipped with dual silica layers coated upconversion nanoparticles (UCNPs) as nanocarriers modified with N‐p‐Tosylglycine, in which the dense silica for chlorin e6 (Ce6) and the glutathione (GSH)‐responsive degradable silica for loading resveratrol (RES) (UCNPs@SiO2‐Ce6@MON(RES)@ER (UCSMRER)). On the one hand, UCSMRER was positioned accurately in the endoplasmic reticulum (ER) guided by the ER‐targeted molecular N‐p‐Tosylglycine. This precise ER‐targeted photodynamic therapy (PDT) could generate reactive oxygen species (ROS) in situ under the 980 nm laser irradiation, which not only induced severe cell death directly but also caused intense ER stress‐based immunogenic cell death (ICD) effects, triggering a tumor immune response. On the other hand, tumor hypoxia aggravated by the PDT process was effectively alleviated by RES released on‐demand, which reduced oxygen consumption by impairing the mitochondrial electron transport chain (ETC). This integrated precise ER‐targeted and oxygen‐compensated strategy maximized the PDT effect and potentiated ICD‐associated immunotherapy, which availed to attenuate ITME, activate tumor immunogenicity and further magnify anti‐tumor effect. This innovative concept about PDT and immunotherapy sheds light on the cancer‐related clinical application. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
Tumor Selective Metabolic Reprogramming as a Prospective PD‐L1 Depression Strategy to Reactivate Immunotherapy

Yu Liu,Zaigang Zhou,Jiting Hou,Wei Xiong,Heejeong Kim,Jiashe Chen,Chunjuan Zheng,Xin Jiang,Juyoung Yoon,Jianliang Shen

DOI: https://doi.org/10.1002/adma.202206121

IF: 29.4

2022-08-28

Advanced Materials

Abstract:Currently, the role of the lysosome, endoplasmic reticulum (ER), or dictyosome in the transcription and translation of Programmed cell death ligand 1 (PD‐L1) was well revealed, but the role and function of mitochondria in the PD‐L1 expression in tumors was still not fully researched, making it hard to offer a novel PD‐L1 regulation strategy. In this research, we newly revealed that mitochondria oxidative phosphorylation (OXPHOS) depression could be used as an effective PD‐L1 downregulation method. To offer an ideal and high‐effective tumor mitochondria‐targeted OXPHOS depression nanosystem, IR‐LND was prepared by conjugating mitochondria‐targeted heptamethine cyanine dye IR‐68 with mitochondrial complexes I and II depression agent Lonidamine (LND), which then further self‐assembled with albumin (Alb) to form IR‐LND@Alb nanoparticles. By doing this, PD‐L1 expression in tumors was selectively and effectively depressed by IR‐LND@Alb nanoparticles. As we expected, the anti‐tumor efficacy of such a PD‐L1 depression strategy was superior to conventional anti‐PD‐L1 monoclonal antibodies. Interestingly, IR‐LND could also be served as a novel ideal promising photodynamic therapy (PDT) drug with self‐oxygen and self‐PD‐L1 regulation capacity. All in all, this tumor‐selective metabolic reprogramming platform to reactivate immunotherapy and sensitize for PDT effect, which would open a new window for mitochondrial immunotherapy for cancer patients. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
A combination of PD-L1-targeted IL-15 mRNA nanotherapy and ultrasound-targeted microbubble destruction for tumor immunotherapy

Xiaoxuan Wang,Fangxuan Li,Jialu Zhang,Lu Guo,Mengmeng Shang,Xiao Sun,Shan Xiao,Dandan Shi,Dong Meng,Yading Zhao,Chao Jiang,Jie Li

DOI: https://doi.org/10.1016/j.jconrel.2024.01.039

IF: 11.467

2024-03-01

Journal of Controlled Release

Abstract:PD-1/PD-L1-based immune checkpoint blockade therapy has shown limited benefits in tumor patients, partially attributed to the inadequate infiltration of immune effector cells within tumors. Here, we established a nanoplatform named DPPA/IL-15 NPs to target PD-L1 for the tumor delivery of IL-15 messenger RNA (mRNA). DPPA/IL-15 NPs were endowed with ultrasound responsiveness and contrast-enhanced ultrasound (CEUS) imaging performance. They effectively protected IL-15 mRNA from degradation and specifically transfected it into tumor cells through the utilization of ultrasound-targeted microbubble destruction (UTMD). This resulted in the activation of IL-15-related immune effector cells while blocking the PD-1/PD-L1 pathway. In addition, UTMD could generate reactive oxygen species (ROS) that induce endoplasmic reticulum (ER) stress-driven immunogenic cell death (ICD), initiating anti-tumor immunity. In vitro and in vivo studies revealed that this combination therapy could induce a robust systemic immune response and enhance anti-tumor efficacy. Thus, this combination therapy has the potential for clinical translation through enhanced immunotherapy and provides real-time ultrasound imaging guidance.

pharmacology & pharmacy,chemistry, multidisciplinary
A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.

Mei-Zhen Zou,Wen-Long Liu,Chu-Xin Li,Di-Wei Zheng,Jin-Yue Zeng,Fan Gao,Jing-Jie Ye,Xian-Zheng Zhang

DOI: https://doi.org/10.1002/smll.201801120

IF: 13.3

2018-01-01

Small

Abstract:Hypoxia is reported to participate in tumor progression, promote drug resistance, and immune escape within tumor microenvironment, and thus impair therapeutic effects including the chemotherapy and advanced immunotherapy. Here, a multifunctional biomimetic core-shell nanoplatform is reported for improving synergetic chemotherapy and immunotherapy. Based on the properties including good biodegradability and functionalities, the pH-sensitive zeolitic imidazolate framework 8 embedded with catalase and doxorubicin constructs the core and serves as an oxygen generator and drug reservoir. Murine melanoma cell membrane coating on the core provides tumor targeting ability and elicits an immune response due to abundance of antigens. It is demonstrated that this biomimetic core-shell nanoplatform with oxygen generation can be partial to accumulate in tumor and downregulate the expression of hypoxia-inducible factor 1α, which can further enhance the therapeutic effects of chemotherapy and reduce the expression of programmed death ligand 1 (PD-L1). Combined with immune checkpoints blockade therapy by programmed death 1 (PD-1) antibody, the dual inhibition of the PD-1/PD-L1 axis elicits significant immune response and presents a robust effect in lengthening tumor recurrent time and inhibiting tumor metastasis. Consequently, the multifunctional nanoplatform provides a potential strategy of synergetic chemotherapy and immunotherapy.
Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity

Jingjing Liang,Huifang Wang,Wenxiu Ding,Jianxiang Huang,Xuefei Zhou,Huiyang Wang,Xue Dong,Guangyao Li,Enguo Chen,Fei Zhou,Hongjie Fan,Jingya Xia,Bo Shen,Da Cai,Pengxun Lan,Hanliang Jiang,Jun Ling,Zhen Cheng,Xiangrui Liu,Jihong Sun

DOI: https://doi.org/10.1126/sciadv.abc3646

2020-08-28

Abstract:Mounting evidence suggests that immunotherapies are a promising new class of anticancer therapies. However, the immunosuppressive tumor microenvironment (TME), poor immunogenicity, and off-target toxicity hinder the broader implementation of immunotherapies. Here, we describe a novel strategy combining chemotherapy and immunotherapy to modulate the TME by systemically and concurrently delivering the chemotherapeutic agent SN38 (7-ethyl-10-hydroxycamptothecin) and the STING agonist DMXAA (5,6-dimethylxanthenone-4-acetic acid) into tumors using triblock copolymer nanoparticles, named PS3D1@DMXAA, which enhances antigen cross-presentation and induces the conversion of the immunosuppressive TME to immunogenic TME through the newly found synergistic function between SN38 and STING activation. PS3D1@DMXAA thus shows potent therapeutic efficacy in three mice tumor models and elicits remarkable therapeutic benefit when combined with anti-PD-1 therapy. Our engineered nanosystem offers a rational design of an effective immunotherapy combination regimen to convert uninflamed "cold" tumors into "hot" tumors, addressing the major challenges immunotherapies faced.
Programmed Nanoreactors Boost Immune Response through ROS Cascade Amplification along with RNS Storm

Haina Tian,Yang Li,Jinyan Lin,Fukai Zhu,Zhenqing Hou,Peiyuan Wang,Xiaolong Liu

DOI: https://doi.org/10.1021/acsmaterialslett.3c00676

IF: 11.4

2023-08-18

ACS Materials Letters

Abstract:High oxidative stress plays a significant role in activating intracellular signaling pathways that govern immunogenic cell death (ICD). Nevertheless, immune response is often confined by limited reactive oxygen species (ROS) production, upregulated antioxidant defense, and an immunosuppressive tumor microenvironment. Herein, the GSH/pH-sensitive Mn2+/polydopamine-incorporated hollow mesoporous tetrasulfide-bridged organosilica nanoreactors loaded with l-arginine (l-Arg) were successfully constructed (A@MnHMONs-PEG). Under near-infrared light (NIR) illumination, the programmed nanoreactors directly generate a large amount of ROS via “Mn2+-based Fenton-like catalysis and tetrasulfide bridge-mediated GSH depletion” for photothermal-intensified chemodynamic therapy, meanwhile ROS could oxidize the guanidine groups of l-Arg to produce nitric oxide (NO) for gas therapy. Moreover, both photothermal and massive ROS substantially induce cancer immune responses by up-regulating ICD. Furthermore, the more powerful peroxynitrite anion (ONOO–) is sequentially generated through the interaction of ROS and NO. It could polarize macrophages from M2 into M1 phenotype to reverse immunosuppression and enhance immune response. In vivo experiments conclusively prove that our programmed nanoreactors could combine photothermal-chemodynamic-NO therapy and concurrently enhance immune response via ROS cascade amplification along with ONOO– storm for elimination of the primary tumor and inhibition of recurrence/metastasis. Our programmed nanoreactors open up new paths for improving the anticancer immune response.

materials science, multidisciplinary
"Butterfly-effect" nano-platforms for cascade immune amplification and tumor clearance through multi-modal therapy and immune sensitization

Haoyu Chen,Xiaoying Kong,Jiahui Yan,Tianyi Wang,Yaqian Lv,Fenglang Zhang,Danping Liu,Yingshan Qu,Jun Fu,Wei Han,Jinsheng Shi

DOI: https://doi.org/10.1016/j.cej.2024.153103

IF: 15.1

2024-06-22

Chemical Engineering Journal

Abstract:Combined dynamic tumor therapy of photodynamic therapy (PDT), sonodynamic therapy (SDT) and microwave dynamic therapy (MDT) can overcome the limitations of single reactive oxygen species (ROS)-based therapy (including limited tissue penetration depth and low ROS production). However, changes in the tumor microenvironment caused by ROS amplification and oxygen depletion induce severe immunosuppression at the tumor site, indicating effective immunosensitization of the tumors are urgently needed. Here, melanin-hematoporphyrin-chloroquine R837-hyaluronic acid (MHRH) nanoplatform that can simultaneously respond to 980 nm laser /1064 nm laser/ultrasonic/microwave was prepared for PDT/SDT/MDT, achieving outbreak of ROS in deep tumor. More importantly, the photothermal ablation and the participation of chloroquine R837 of MHRH NPs reversed the immunosuppression caused by oxygen depletion after ROS outbreak by promoting DCs maturation and secretion of macrophage exosomes. In summary, the natural MHRH nano-platform supplies an obvious anti-tumor "butterfly effect" through ROS outbreak, thermal ablation and significant immunosuppressive reversal, which provides a new and promising combined strategy of ROS-dynamic therapy and immune agonists in deep tumor tissues.

engineering, chemical, environmental
Antitumor Effects of a Distinct Sonodynamic Nanosystem through Enhanced Induction of Immunogenic Cell Death and Ferroptosis with Modulation of Tumor Microenvironment

Haitao Yuan,Jingbo Ma,Wei Huang,Ping Gong,Fei Shi,Xiaolong Xu,Chunjin Fu,Xiaoxian Wang,Yin Kwan Wong,Ying Long,Xin Sun,Weihua Li,Zhijie Li,Jigang Wang

DOI: https://doi.org/10.1021/jacsau.3c00156

IF: 8

2023-05-09

JACS Au

Abstract:Sonodynamic therapy (SDT) holds great promise to be applied for cancer therapy in clinical settings. However, its poor therapeutic efficacy has limited its applications owing to the apoptosis-resistant mechanism of cancer cells. Moreover, the hypoxic and immunosuppressive tumor microenvironment (TME) also weakens the efficacy of immunotherapy in solid tumors. Therefore, reversing TME remains a formidable challenge. To circumvent these critical issues, we developed an ultrasound-augmented strategy to regulate the TME by utilizing an HMME-based liposomal nanosystem (HB liposomes), which can synergistically promote the induction of ferroptosis/apoptosis/immunogenic cell death (ICD) and initiate the reprograming of TME. The RNA sequencing analysis demonstrated that apoptosis, hypoxia factors, and redox-related pathways were modulated during the treatment with HB liposomes under ultrasound irradiation. The in vivo photoacoustic imaging experiment showed that HB liposomes enhanced oxygen production in the TME, alleviated TME hypoxia, and helped to overcome the hypoxia of the solid tumors, consequently improving the SDT efficiency. More importantly, HB liposomes extensively induced ICD, resulting in enhanced T-cell recruitment and infiltration, which normalizes the immunosuppressive TME and facilitates antitumor immune responses. Meanwhile, the HB liposomal SDT system combined with PD1 immune checkpoint inhibitor achieves superior synergistic cancer inhibition. Both in vitro and in vivo results indicate that the HB liposomes act as a sonodynamic immune adjuvant that is able to induce ferroptosis/apoptosis/ICD via generated lipid-reactive oxide species during the SDT and reprogram TME due to ICD induction. This sonodynamic nanosystem integrating oxygen supply, reactive oxygen species generation, and induction of ferroptosis/apoptosis/ICD is an excellent strategy for effective TME modulation and efficient tumor therapy.

English Else
Conservation status of Chinese species: (2) Invertebrates.

Yan Xie,Sung Wang

DOI: https://doi.org/10.1111/j.1749-4877.2007.00046.x

2007-06-01

Integrative Zoology

Abstract:A total of 2441 invertebrate species were evaluated using the IUCN Red List Criteria and Regional Guidelines. Approximately 30 experts were involved in this project, which covered a wide range of species, including jellyfish, corals, planarians, snails, mollusks, bivalves, decapods, benthic crustaceans, arachnids (spiders, scorpions), butterflies, moths, beetles, sea cucumbers, sea urchins, sea stars, acorn worms and lancelets. In general, invertebrate species in China were found to be severely threatened, with 0.9% being critically endangered, 13.44% endangered and 20.63% vulnerable. All species of hermatypic corals and planarians are threatened. More than 80% of evaluated species face serious threat due to habitat destruction by coral collection, logging, non-woody vegetation collection, timber plantations, non-timber plantations, extraction and/or livestock. Other threats are intrinsic factors, harvesting by humans, alien invasive species and pollution. The main intrinsic factors contributing to the high levels of threat are limited dispersal and restricted range. No conservation measures have been taken for 70% of the threatened invertebrates evaluated. Existing conservation measures include: strengthening of national and international legislation (Convention on International Trade in Endangered Species of Wild Fauna and Flora), increasing public awareness, studying population trends/monitoring, and establishment of protected areas. The major conservation measure employed is strengthening of policies. Relative to the situation worldwide (2006 IUCN Red List), there is little information available about invertebrate extinctions in China.
In Situ STING‐Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti‐PD‐1‐Resistant Tumors

Beibei Zhang,Juan Zhang,Yaqiong Li,Na Li,Yuzhou Wang,Ru Jang,Xiaoxia Xu,Ruifang Li,Zhenzhen Chen,Shaobo Duan,Yongchao Wang,Lianzhong Zhang

DOI: https://doi.org/10.1002/adma.202300171

IF: 29.4

2023-04-14

Advanced Materials

Abstract:Immunotherapies comprising programmed cell death protein 1/PD ligand 1 (PD‐1/PD‐L1) immune checkpoint inhibitors are effective cancer treatments. However, the low response rate and immunoresistance resulting from alternative immune checkpoint upregulation and inefficient immune stimulation by T cells are problematic. The present report describes a biomimetic nanoplatform that simultaneously blocks the alternative T cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT) checkpoint and activates the stimulator of interferon genes (STING) signaling pathway in situ for enhanced antitumor immunity. The nanoplatform is engineered by fusing a red blood cell membrane with glutathione‐responsive liposome encapsulated cascade‐activating chemo‐agents (β‐lapachone and tirapazamine), and anchoring them with a detachable TIGIT block peptide (named as RTLT). In the tumor environment, the peptide was spatiotemporally released to reverse T‐cell exhaustion and restore antitumor immunity. The cascade activation of chemotherapeutic agents caused DNA damage and inhibited the repair of double‐stranded DNA, which induced robust in situ STING activation for an efficient immune response. The RTLT inhibited anti‐PD‐1‐resistant tumor growth, and prevented tumor metastasis and recurrence in vivo by inducing antigen‐specific immune memory. This biomimetic nanoplatform thus provides a promising strategy for in situ cancer vaccination. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology

[Neuro-endocrine disorders in cardiac insufficiency: therapeutic consequences].

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

An Oxidative Stress Nano-Amplifier for Improved Tumor Elimination and Combined Immunotherapy

A Novel Nanomedicine Integrating Ferroptosis and Photothermal Therapy, Well-Suitable for PD-L1-mediated Immune Checkpoint Blockade

PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy

Radiation-activated PD-L1 aptamer-functionalized nanoradiosensitizer to potentiate antitumor immunity in combined radioimmunotherapy and photothermal therapy

Nanomedicine Integrating the Lipidic Derivative of 5-Fluorouracil, Miriplatin and PD-L1 Sirna for Enhancing Tumor Therapy

Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer

Nrf2 silencing amplifies DNA photooxidative damage to activate the STING pathway for synergistic tumor immunotherapy

A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy

Peptide-Appended Nanosonosensitizers Targeting Tumor Glycolysis for Synergistic Sonodynamic-Immunometabolic Therapy of Spinal-Metastasized Tumors

Rationally Integrated Precise ER‐targeted And Oxygen‐compensated Photodynamic Immunostimulant for Immunogenicity‐boosted Tumor Therapy

Tumor Selective Metabolic Reprogramming as a Prospective PD‐L1 Depression Strategy to Reactivate Immunotherapy

A combination of PD-L1-targeted IL-15 mRNA nanotherapy and ultrasound-targeted microbubble destruction for tumor immunotherapy

A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.

Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity

Programmed Nanoreactors Boost Immune Response through ROS Cascade Amplification along with RNS Storm

"Butterfly-effect" nano-platforms for cascade immune amplification and tumor clearance through multi-modal therapy and immune sensitization

Antitumor Effects of a Distinct Sonodynamic Nanosystem through Enhanced Induction of Immunogenic Cell Death and Ferroptosis with Modulation of Tumor Microenvironment

Conservation status of Chinese species: (2) Invertebrates.

In Situ STING‐Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti‐PD‐1‐Resistant Tumors